David Meeker, Rhythm Pharmaceuticals CEO
June 20, 2023 06:51 AM EDT
R&D

Rhythm’s Im­civree shows off con­tin­ued BMI de­crease in rare obe­si­ty con­di­tion

Katherine Lewin

News Reporter

Rhythm Phar­ma­ceu­ti­cals’ ge­net­ic obe­si­ty drug hit an­oth­er mile­stone with the re­lease of da­ta show­ing “mean­ing­ful weight loss” in a small ex­ten­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times